Specifically in AML, SCD has been shown to play a role in the resistance of AML stem cells to NAMPT inhibitors [14], while SCD inhibition (SCDi) leads to greater sensitivity to FLT3 inhibitors [15]. The gene discussed is FLT3; the disease is acute myeloid leukemia.